Heim600664 • SHA
add
Harbin Pharmaceutical Group Co Ltd
Við síðustu lokun
3,65 ¥
Dagbil
3,59 ¥ - 3,67 ¥
Árabil
2,54 ¥ - 4,97 ¥
Markaðsvirði
9,07 ma. CNY
Meðalmagn
55,85 m.
V/H-hlutf.
13,63
A/V-hlutfall
-
Aðalkauphöll
SHA
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CNY) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 4,17 ma. | 0,78% |
Rekstrarkostnaður | 826,11 m. | -13,16% |
Nettótekjur | 212,93 m. | 20,48% |
Hagnaðarhlutfall | 5,10 | 19,44% |
Hagnaður á hvern hlut | — | — |
EBITDA | 346,87 m. | 20,82% |
Virkt skatthlutfall | 19,49% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CNY) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 2,80 ma. | -1,58% |
Heildareignir | 14,09 ma. | -0,38% |
Heildarskuldir | 7,79 ma. | -8,76% |
Eigið fé alls | 6,31 ma. | — |
Útistandandi hlutabréf | 2,66 ma. | — |
Eiginfjárgengi | 1,75 | — |
Arðsemi eigna | 4,99% | — |
Ávöxtun eigin fjár | 9,23% | — |
Peningaflæði
Breyting á handbæru fé
| (CNY) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 212,93 m. | 20,48% |
Handbært fé frá rekstri | -464,57 m. | -71,56% |
Reiðufé frá fjárfestingum | -17,57 m. | -19,17% |
Reiðufé frá fjármögnun | -271,12 m. | -314,72% |
Breyting á handbæru fé | -753,69 m. | -372,72% |
Frjálst peningaflæði | -513,00 m. | -5,30% |
Um
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate.
The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
Stofnsett
1988
Vefsvæði
Starfsfólk
10.180
